Seres Therapeutics, Inc.
MCRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $144,927 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $3,532 | $0 | $0 | $0 |
| Gross Profit | -$3,532 | $0 | $0 | $144,927 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $64,600 | $117,597 | $109,651 | $141,891 |
| G&A Expenses | $53,183 | $77,500 | $70,263 | $69,261 |
| SG&A Expenses | $53,183 | $77,500 | $70,263 | $69,261 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1,732 |
| Operating Expenses | $117,783 | $195,097 | $179,914 | $209,420 |
| Operating Income | -$121,315 | -$195,097 | -$179,914 | -$64,493 |
| % Margin | – | – | – | -44.5% |
| Other Income/Exp. Net | -$4,456 | $4,967 | -$3,667 | -$1,085 |
| Pre-Tax Income | -$125,771 | -$190,130 | -$183,581 | -$65,578 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $136 | -$113,724 | -$250,157 | -$65,578 |
| % Margin | – | – | – | -45.2% |
| EPS | -18.864 | -17.769 | -46.292 | -14.302 |
| % Growth | -6.2% | 61.6% | -223.7% | – |
| EPS Diluted | -18.864 | -17.769 | -46.292 | -14.302 |
| Weighted Avg Shares Out | 7,770 | 6,400 | 5,404 | 4,585 |
| Weighted Avg Shares Out Dil | 7,770 | 6,400 | 5,404 | 4,585 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,967 | $7,301 | $3,058 | $2,870 |
| Interest Expense | $0 | $13,176 | $6,020 | $2,910 |
| Depreciation & Amortization | $5,468 | $6,243 | $6,629 | $5,947 |
| EBITDA | -$120,303 | -$181,419 | -$170,932 | -$56,721 |
| % Margin | – | – | – | -39.1% |